Targeting CSC-Specific Surface Markers

Identifying unique surface markers expressed by cancer stem cells (CSCs) is key to selectively targeting them without affecting normal stem cells. This track focuses on the discovery of CSC-specific markers such as CD44, CD133, and ALDH1. Researchers aim to develop targeted therapies, including monoclonal antibodies and small molecules, that can specifically recognize and eliminate CSCs. By utilizing these markers for drug delivery or immunotherapy, more precise and effective cancer treatments can be designed. The goal is to reduce tumor recurrence and improve treatment efficacy by targeting the CSC population while sparing healthy tissue, offering a promising approach to cancer therapy.

    Related Conference of Targeting CSC-Specific Surface Markers

    March 10-11, 2025

    3rd World Congress on Oral Cancer

    Paris, France
    March 24-25, 2025

    25th World Congress on Cancer and Diagnostics

    London, UK
    March 24-25, 2025

    10th World Conference on Breast and Cervical Cancer

    Paris, France
    April 07-08, 2025

    15th World Congress on Breast Cancer

    Vancouver, Canada
    April 28-29, 2025

    35th Experts Meet On Cancer Research & Therapy

    Aix-en-Provence, France
    June 16-17, 2025

    26th World Congress on Cancer Summit

    Amsterdam, Netherlands
    July 14-15, 2025

    5th World Congress on Breast Cancer

    Berlin, Germany
    July 28-29, 2025

    45th Euro Congress on Cancer Science & Therapy

    Aix-en-Provence, France
    October 20-21, 2025

    21st International Conference on Cancer Research

    Barcelona, Spain

    Targeting CSC-Specific Surface Markers Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in